Compare LPTH & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | FULC |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.1M | 535.5M |
| IPO Year | 2011 | 2019 |
| Metric | LPTH | FULC |
|---|---|---|
| Price | $14.53 | $7.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $13.33 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 2.2M | 879.1K |
| Earning Date | 05-14-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,202,630.00 | N/A |
| Revenue This Year | $83.04 | N/A |
| Revenue Next Year | $24.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $2.25 | $3.39 |
| 52 Week High | $15.72 | $15.74 |
| Indicator | LPTH | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 63.58 | 48.40 |
| Support Level | $9.60 | $7.40 |
| Resistance Level | $15.24 | $8.20 |
| Average True Range (ATR) | 1.25 | 0.46 |
| MACD | 0.24 | 0.06 |
| Stochastic Oscillator | 80.43 | 41.12 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.